The heatmap of genes similar to the ASCL2 in STAD is shown in Fig. 1C. The receiver operating characteristic (ROC) curve of the ASCL2 in STAD is shown in Fig. 1D. Based on the analyses of the overall survival (OS), first progressive survival (FPS), and post-progressive survival (PPS), we can easily infer that when the expression of the ASCL2 isoform is high (Fig. 1E–G), high levels of the ASCL2 STAD patients have a worse prognostic outcome (P < 0.05). This evidence concerns the gene ASCL2 and gastric adenocarcinoma.